Next-Generation VNS System and Implantable Device Approved

Monday, October 09, 2017 | Epilepsy & Seizure Disorders , FDA Approval/Clearance , Product Launches and Updates


LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiva implantable device, the smallest and lightest responsive therapy for epilepsy. The new VNS Therapy system features a wireless wand and new user interface on a small tablet, while the SenTiva device includes detect-and-respond mode designed to prevent seizures before they start and automatically deliver extra therapy to stop them if they do. The device also collects and logs events commonly associated with seizures, including a patient’s body position and heart rate variations. When the new VNS system andSenTiva are combined, physicians can utilize advanced options, such as guided and scheduled programming. The VNS Therapy Programming System is also compatibly with all LivaNova legacy VNS Therapy generators, allowing physicians to use the system with numerous patients.

Next Story

Comments

You must be logged in to leave a comment.